Skip to content

July 2015

By Simon Collins and Tim Horn


As a global community of people living with HIV, our needs from the antiretroviral (ARV) pipeline have changed considerably over the last 20 years.

Antiretroviral treatment (ART), particularly for people starting treatment, is increasingly effective, safe, and easier to take. ART now involves fewer pills and doses, with several combinations combined in a single daily pill. This may have raised the bar for drug research and development, with only those compounds with clear advantages progressing to clinical trials, but by definition, this has always been the case. Just as importantly, technological and scientific advances should enable companies to continue to design even better and more effective drugs.

Although current treatments are largely manageable, side effects continue to be a concern, especially when combination therapy will be taken for decades. Drug interactions are complex, even with some recently approved drugs. This is increasingly significant given the greater rates of complications and polypharmacy as we grow older. Drug interactions are also important because of the increasing role played by non-HIV specialists in HIV management, especially primary care providers. The strictness required to maintain long-term adherence continues; most once-daily combinations still involve being taken every 24 hours rather than “any time,” and many drugs still must be taken with food.

Critically for 2015 – and annually going forward – manufacturers need to market new drugs at prices that are not just competitive but affordable. This is particularly true given the results from the Strategic Timing of Antiretroviral Treatment (START) study, which support starting HIV therapy regardless of baseline CD4 count.1,2 The DSMB interim analysis, demonstrating a 53% reduction in the risk of developing serious illness or death in the early-treatment group (95% CI: 0.32–0.68, P < 0.001) compared with those in the deferred group, is expected to change ARV treatment guidelines in high-, middle-, and low-income countries. Overnight, this will substantially increase the number of people who will be eligible for treatment and the budgets required to meet this need.

The use of generic versions of widely used ARVs in high-income countries warrants a specific focus. Although they are bioequivalent, generics are technically new formulations. The dramatically lower prices in some countries have the potential to further widen the difference between standards of care for people who are rich or well insured compared with those dependent on public health providers. With nearly all health systems under pressure to save costs, certainly in Europe, this will bring a new dynamic to HIV management.

However, at least in the United States, launch prices continue to spiral upward – directly related to the wholesale acquisition cost established for a previously approved drug, irrespective of the active pharmaceutical ingredient (API) or the potential for high-volume sales – and annual (and sometime twice-yearly) price increases far exceed all medical consumer price index categories.

It is significant that the U.S. Department of Health and Human Service’s Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents 2015 update relegated Atripla to an alternative option. Although efavirenz is in now off patent in some countries in Europe, the U.S. patent has been extended to 2017, for reasons that are unclear.

Whether guideline recommendations alone will be sufficient to shift the majority of new prescriptions to one of the four integrase-based combinations or to darunavir/ritonavir plus tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) is also unclear. Similar discussions are likely to occur when TDF, which has been a preferred regimen component since U.S. approval in 2001, comes off patent in 2017. A new prodrug of tenofovir, tenofovir alafenamide fumarate (TAF), is covered later in this report to discuss whether it brings important clinical advantages for some or all patients or whether it is merely a way to extend patent exclusivity.

Even fixed-dose combinations (FDCs), clearly popular for anyone taking treatment, are undergoing more rigorous scrutiny, including whether, in the absence of evidence showing clinical benefits, the common-sense advantages of reduced pill count will be sufficient to justify continued access at higher prices than for matched generics.3,4 Also, for the first time, branded drugs are being co-formulated with generics for high-income markets.

Against this background, the antiretroviral pipeline in 2015 is surprisingly encouraging. It features compounds in phase II/III development that might bring important improvements for treatment. These include Gilead Science’s TAF, ViiV Healthcare’s cabotegravir (in oral and long-acting injection formulations), and Janssen’s long-acting rilpivirine formulation. Of particular interest for the important group of people with resistance to current drugs, Bristol-Myers Squibb (BMS) has an attachment inhibitor, fostemsavir, and a maturation inhibitor, BMS-955176, and Merck is progressing with the non-nucleoside reverse transcriptase inhibitor (NNRTI) doravirine.


A summary of key developments since the 2014 Pipeline Report is included in table 1. Study details, references, and timelines for compounds with significant advances over the past year are discussed in greater detail in the text below.

Table 1. Summary of Pipeline Compounds in 2015






tenofovir alafenamide fumarate (TAF)

(tenofovir prodrug)


NDA filed/Phase III

NDA filed in U.S. for 4-drug elvitegravir/cobicistat/FTC/TAF (E/C/F/TAF) in November 2014, 2-drug FTC/TAF in April 2015, and 3-drug rilpivirine/F/TAF in July 2015. Decisions will take 12 months. Phase III studies include: E/C/F/TAF in treatment-experienced patients and darunavir/FTC/TAF

doravirine (MK-1439)



Phase III

Once-daily NNRTI with comparable efficacy to efavirenz. Phase III studies include head-to-head against darunavir/ritonavir in experienced patients and combined in an FDC with generic TDF and 3TC


Attachment inhibitor (gp120)


Phase III

Phase II data at CROI 2015 reported comparable efficacy to atazanavir/ritonavir in experienced patients. International phase III study in people with multidrug resistance (>2 class) opened February 2015

raltegravir (once-daily formulation,
2 X 600 mg tablets)



Phase III

Ongoing phase III noninferiority study comparing once- vs. twice-daily raltegravir has primary outcome results expected in early 2016

cenicriviroc (TBR-652)

CCR5 inhibitor (also active against CCR2)


Phase II

No new clinical data since phase II study results in 2013. Current phase II studies are in neurocognitive impairment or NASH. Plans to study co-formulation with 3TC have not developed


Maturation inhibitor


Phase II

Phase II trial in experienced patients under way. Phase III evaluations in naïve and experienced patients planned




Phase IIb

3TC-like molecule, stalled at phase IIb with no new studies since 2009; active against some NRTI resistance but limited financial backing

PRO 140

CCR5-specific humanized monoclonal antibody


Phase II

No new data since 2010. Phase II trials, including adjunctive therapy and treatment substitution evaluations, are planned or under way

ibalizumab (TMB-355; formerly TNX-355)

humanized IgG4 monoclonal antibody

TaiMed Biologics

Phase II/III

Orphan drug designation was granted by the FDA in October 2014. Compassionate access is listed as phase III, but there are no stand-alone studies

cabotegravir oral and long-acting (LA) formulations

INSTI (follow-up to dolutegravir)

ViiV Healthcare

Phase IIb

96-week phase IIb results at CROI 2015 support once-daily maintenance therapy at 30 mg dose paired with oral rilpivirine; cabotegravir LA with rilpivirine LA in phase II studies

rilpivirine LA formulation



Phase II

Follow-up data supporting daily oral dosing as maintenance therapy paired with oral cabotegravir presented at CROI 2015; rilpivirine LA with cabotegravir LA now in phase II studies




Phase II

A follow-up to elvitegravir that does not require boosting. Being compared with dolutegravir in ongoing phase II study with 24-week primary endpoint results expected early 2016

(formerly festinavir/BMS-986001/OBP-601)



Phase IIb

This d4T-like molecule had similar efficacy but increased side effects and drug resistance compared with tenofovir in a phase 2b study presented at ICAAC 2014. BMS has dropped the option to develop. May have role in HIV-2

dolutegravir plus rilpivirine


ViiV Healthcare, Janssen

Phase I

A phase I bioavailability study in HIV-negative volunteers is under way for this dual formulation. The dual combination, using separate oral drugs as maintenance therapy, is the focus of several other ongoing studies


fusion inhibitor

Frontier Biotechnologies

Phase I

Though no new data have been reported since 2012, a phase III trial is currently under way in China. U.S./E.U. development and regulatory plans remain unclear




Phase I

No new data or studies announced since 2013 Pipeline Report

BMS: Bristol-Myers Squibb
CROI: Conference on Retroviruses and Opportunistic Infections
FDA: Food and Drug Administration (United States)
FDC: fixed-dose combination
ICAAC: Interscience Conference of Antimicrobial Agents and Chemotherapy
INSTI: integrase strand transfer inhibitor (integrase inhibitor)
LA: long-acting
NASH: nonalcoholic steatohepatitis
NDA: new drug application
NNRTI: non-nucleoside reverse transcriptase inhibitor
NRTI: nucleoside reverse transcriptase inhibitor
NtRTI: nucleotide reverse transcriptase inhibitor
TAF: tenofovir alafenamide fumarate
TDF: tenofovir disoproxil fumarate


Four new co-formulations were granted marketing clearance since the last Pipeline Report was published in July 2014.


The FDC of dolutegravir/abacavir/3TC, brand name Triumeq, was approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) in August and September 2014, respectively.5,6 Approval was primarily based on previously published data from the phase III SINGLE dolutegravir registrational study plus a new bioequivalence evaluation of the FDC compared with the three single drugs.7

Triumeq is manufactured by ViiV Healthcare and is one of four integrase strand transfer inhibitor (INSTI)-inclusive regimens recommended as first-line therapy for antiretroviral-naive people in the April 2015 update to the U.S. Department of Health and Human Services’ Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents.8 It is also one of three regimens recommended as first-line therapy – all INSTI-inclusive ARV combinations – in Spain’s 2015 treatment guidelines.9


The dual formulation of darunavir/cobicistat was approved by Health Canada in June 2014, the EMA in November 2014, and the FDA in March 2015.10,11,12

Manufactured by Janssen, the trade name is Prezcobix in Canada and the United States and Rezolsta in the European Union. Approval was based on phase I bioequivalence data of the FDC compared with single drugs in HIV-negative volunteers, and the decisions emphasized the continued need to take darunavir with food. Approval was also based on efficacy results from a single-arm study in 313 HIV-positive people (94% were treatment-naive) with viral load >1,000 copies/mL and estimated glomerular filtration rate (eGFR) >80 mL/min.13,14

Darunavir/ritonavir, combined with TDF/FTC, is the only non-INSTI third drug to remain listed as recommended for ARV-naive people in the April 2015 update to the U.S. Guidelines.8 Prezcobix, however, is listed as an alternative option for use in combination with TDF/FTC or abacavir/3TC, due in part to the less stringent open-label, single-arm safety and efficacy trial completed for regulatory approval.


The dual formulation of atazanavir and cobicistat was approved by the FDA in January 2015.15 EMA review was submitted in 2014 and was still ongoing as this report went to press.

The FDC is manufactured by Bristol-Myers Squibb with the trade name Evotaz. Approval was based on data from registrational studies for cobicistat and new bioequivalence data comparing the FDC with atazanavir and cobicistat coadministered as separate drugs.16

Atazanavir/cobicistat, combined with TDF/FTC, is ranked as an alternative component of first-line therapy in the April 2015 U.S. Guidelines, though only for people with pretreatment estimated creatinine clearance of >70 mL/min. This led to its being listed as a third-tier/“other” option and only when used in combination with abacavir/3TC.8

Boosted atazanavir is used less frequently than darunavir/ritonavir due to higher side effect–related discontinuations, as documented in ACTG A5257.17


The dual formulation of raltegravir and 3TC was approved by the FDA in February 2015 with an indication for use in combination with other ARVs.18 It was submitted to the EMA in March 2014, with a decision expected as this report went to press.

Manufactured by Merck, with the trade name Dutrebis, this is the first co-formulation containing a patent-protected originator drug (raltegravir) with a generic drug (3TC) that was previously developed by another company.

Co-formulating branded products and generics is a strategy that is expected to continue as other ARVs come off patent (see cenicriviroc and doravirine, below). That said, Merck has not marketed Dutrebis in the United States due to the lack of a clearly defined population in need; the company may market Dutrebis elsewhere.19

FDA approval of co-formulated raltegravir/3TC was based primarily on a study demonstrating bioequivalence between the FDC and separate raltegravir and 3TC tablets.20 Notably, the improved bioavailability in this new formulation allows a 300 mg dose of raltegravir, compared with 400 mg in the stand-alone formulation.

Single-Drug Approvals: Elvitegravir and Cobicistat

The only new single-drug approvals in the last year were for formulations of elvitegravir and cobicistat in the United States.21,22

Each of these single drugs was approved by the EMA a year earlier, and demand was so low that in Europe elvitegravir is currently available only by special arrangement with the manufacturer.


TAF Co-formulations

TAF is a new version of tenofovir and is the pipeline compound closest to regulatory approval. Development was prioritized as an FDC component rather than as a single new drug, and applications for an FDC and in a dual nucleoside reverse transcriptase inhibitor (NRTI) formulation have already been submitted to the FDA. The four-in-one combination of elvitegravir/cobicistat/FTC/TAF (E/C/F/TAF) was filed in November 2014 with a target approval date of November 5, 2015. The dual formulation of FTC/TAF (F/TAF) was filed in April 2015, with an anticipated approval in April 2016.23,24

Both TDF and TAF are prodrugs of tenofovir, which require phosphorylation to tenofovir diphosphate (TFV-DP), the active metabolite. TDF is first converted to tenofovir in the blood, whereas TAF largely undergoes alterations inside lymphocytes and other cells. Compared with TDF, TAF achieves intracellular concentrations of tenofovir that are four to seven times higher at plasma concentrations that are 90% lower.25,26,27

Low-milligram TAF dosing – either 10 mg or 25 mg, depending on the combination – together with reduced tenofovir exposure has the potential to reduce bone and kidney toxicities compared with TDF dosing. The low-milligram dosing also clearly helps with pill size for co-formulations, and using less API has the potential to reduce the cost of generic versions where the marketing price is more closely related to manufacturing costs.

It would be easier to be excited about the potential advantages of TAF over TDF if the development timeline were not based on extending the initial TDF patent despite safety concerns with TDF. Gilead Sciences presented in vitro and animal data for TAF in 2001, but phase I results in humans were not reported until 2011.28,29 That is at least 10 years of accumulated renal and bone toxicity among people living with HIV using TDF while TAF stayed on the shelf.

This coordinated delay means that TAF will become available just as the patent on TDF expires. Using this strategy, Gilead has extended the patent on tenofovir for six years based on the primary patent on TAF – and for longer based on other co-formulations.30


The regulatory submission for E/C/F/TAF is based on noninferiority results compared with E/C/F/TDF (Stribild) at 48 weeks in two randomized, double-blind, placebo-controlled phase III studies in treatment-naive patients (studies 104 and 111). Combined analyses of both studies were reported in two separate sessions at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) – one primarily on efficacy and the other for detailed renal, bone, and lipid results – and final 48-week results were published in April by the Lancet.31,32,33

In the combined studies, 867 treatment-naive participants received E/C/F/TDF, and 866 received E/C/F/TAF. Most were men (85%), and just under half were either black (25%) or Hispanic/Latino/Latina (19%). Median baseline CD4 counts and viral load were 405 cells/mm3 and 38,000 copies/mL, respectively. Approximately 12% of participants had CD4 counts below 200 cells/mm3, and 23% had a viral load above 100,000 copies/mL. Median eGFR was 115 mL/min/1.73 m2 (entry criteria included eGFR >50).

For the primary endpoint of viral efficacy at week 48, viral load was <50 copies/mL in 92% of the E/C/F/TAF group compared with 90% in the E/C/F/TDF group (difference 2.0% [95% CI: 0.7%–4.7%]), meeting criteria for noninferiority. Virological failure occurred in 4% of both groups.

When stratified by baseline viral load above/below 100,000 copies/mL, results were 87% versus 89% (above; difference −1.7% [95% CI: −8.3 to 4.8]) and 94% versus 91% (below; difference 3.1% [95% CI: 0.2–6.0]) in the E/C/F/TAF versus E/C/F/TDF arms, respectively. More than 90% of people in both groups with baseline CD4 counts below 200 cells/mm3 also had undetectable viral loads at the 48-week time point. No clear differences were reported between the two combinations in selected subgroup analyses by age, gender, and race.

CD4 count increases were similar until week 36 but by week 48 were significantly higher in the E/C/F/TAF group (+211 cells/mm3) compared with the E/C/F/TAF group (+181 cells/mm3) (P = 0.024).

Safety and drug resistance results were almost identical for the two FDCs. Moderate-to-severe side effects were rare, occurring in approximately 1% of participants in both groups, as were side effect–related treatment discontinuations. Diarrhea was the most common side effect (18%), followed by nausea (16%) and headache (13%). Discontinuation due to side effects occurred in 0.9% (N = 8) of the E/C/F/TAF group and 1.5% (N = 15) of the E/C/F/TDF group; decreased eGFR (N = 1), nephropathy (N = 1), and renal failure (N = 2) all occurred in the E/C/F/TDF group.

Significant decreases in eGFR associated with the effect of cobicistat on renal tubular secretion of creatinine occurred by week 2 and were largely stable thereafter, but these were significantly more pronounced in the E/C/F/TDF group compared with the E/C/F/TAF group (mean −5 vs. −11.2 mL/min; P < 0.001). Changes in quantitative proteinuria measured by median percentage change in urine protein to creatinine ratio, urine albumin to creatinine ratio, retinol-binding protein (RBP), and beta-2 microglobulin (B2M) were significantly higher in the E/C/F/TDF arm compared with the E/C/F/TAF arm (all P < 0.001). Increases in the two low-molecular-weight proteins RBP and B2M are markers of defective proximal tubular uptake.34

Decreases in bone mineral density (BMD) were more pronounced in the E/C/F/TDF group compared with the E/C/F/TAF group. Though there was evidence of spine and hip BMD loss in both groups, the decreases were significantly more pronounced in the E/C/F/TDF group: −2.86 and −2.95 mean standard deviation percentage change in spine and hip BMD, respectively, versus −1.30 and −0.66 for E/C/F/TAF. Individuals in the E/C/F/TDF group were also more likely to have >3% loss in spine and hip BMD: 45% and 50% versus 26% and 17% in the E/C/F/TAF group.

Participants in the E/C/F/TAF group experienced significantly greater increases in triglyceride (114 vs. 108 mg/dL), total cholesterol (189 vs. 177 mg/dL), low-density lipoprotein (LDL) (115 vs. 109 mg/dL), and high-density lipoprotein (HDL) (51 vs. 48 mg/dL) levels compared with those in the E/C/F/TDF group, which is related to the loss of the lipid-lowering effects of less circulating tenofovir. However, the more clinically important total cholesterol:HDL ratio was similar in both groups: 3.6 at baseline versus 4.7 at week 48.

CROI 2015 also included results from a single-arm, open-label, 96-week phase III switch study to E/C/F/TAF (study 112) in an older population that was more likely to have bone, renal, and lipid concerns.35 Entry criteria included having mild-to-moderate kidney dysfunction defined as eGFR 30–69 mL/min.

The study included 242 participants on otherwise stable treatment: 98% had viral load <50 copies/mL, median CD4 count was 632 cells/mm3, and 65% were using TDF. At baseline, median age was 58 years (IQR 52–65), median eGFR was 54 mL/min (30% were <50 mL/min), 39% had hypertension, and 14% had diabetes.

The primary endpoint was change in eGFR at week 24, and secondary analysis included the week-48 results presented at CROI when 92% of the participants still had viral load <50 copies/mL.

There were no significant changes in eGFR (using either Cockcroft Gault or cystatin C) at week 24 or 48 or in actual GFR in the 32 patients, as measured using iohexol clearance. However, other markers of kidney function significantly improved. Median change in proteinuria at week 48 generally either remained unchanged or improved (for 87% of those with grade 1 [N = 52] and for 73% of those with grade 2 [N = 22]). Results for albuminuria status were similar and only worsened for 5%. Median percentage change in RBP and B2M creatinine ratios reduced by 60%–80% by week 48 (P < 0.001 for all patients combined). These changes occurred in patients with baseline eGFR both under and above 50 mL/min.

Median BMD at week 48 significantly increased by 1.9% (IQR: −0.3 to 4.3) in spine and by 0.9% (IQR: −0.3 to 2.7) in hip (P < 0.001). This is notable given that BMD routinely drops due to aging, HIV, and ART, irrespective of combination. The study did not report on use of bisphosphonates or other bone management interventions that might explain this.

Median changes in lipids increased for all parameters (total cholesterol, LDL, HDL, and triglycerides) for people switching from tenofovir and decreased for people switching from non-TDF combinations. Median change in the total cholesterol:HDL ratio was minimal (0.3% and 0.2% for prior TDF and non-TDF groups).

Taken together, these results suggest that the priority for TAF will be people who already have some degree of renal dysfunction or reduced bone mineral density. This may be another example where use of newer drugs is prioritized for some patient groups.


According to Gilead, the regulatory application for the dual F/TAF is based on four phase III E/C/F/TAF studies (studies 104, 111, and 112 and an adolescent study 106),33,35,36 plus bioequivalence data for F/TAF compared with E/C/F/TAF.

Not included in the new drug application (NDA) are data from study 311-1089, the only safety and efficacy trial evaluating F/TAF in combination with drugs other than elvitegravir/cobicistat, such as the boosted protease inhibitors (PIs) atazanavir, lopinavir, and darunavir and the unboosted drugs efavirenz, raltegravir, dolutegravir, and maraviroc.37 Hence, the FDA is reviewing an NDA for a co-formulation to be used in combination with unboosted third drugs – one requiring a TAF dose (25 mg) higher than that used in E/C/F/TAF (10 mg; Gilead is developing formulations of F/TAF containing both doses) – without the availability of robust data to support this indication.

In fact, all of Gilead’s registrational trials for TAF combined with drugs other than elvitegravir/cobicistat, such as FDCs containing cobicistat/darunavir and rilpivirine, as discussed below, are switch studies.

TAF is a new drug with a unique metabolism and safety profile. The near-complete reliance for approval on switch studies is unprecedented. Similarly, renal data from E/C/F/TAF studies are muddied by cobicistat’s effect on estimated (if not actual) GFR, limiting a complete understanding of TAF as an individual drug.


Several compounds with exciting early data are steadily progressing, and several co-formulations are in advanced phase III studies.

The pipeline can be categorized broadly as in advanced development or progressing in earlier stages.

Advanced: Generally Phase III

  • TAF in other FDCs
    • darunavir/cobicistat/FTC/TAF
    • rilpivirine/FTC/TAF [editor’s note: NDA submitted to the FDA at press time]
  • doravirine
  • fostemsavir
  • cenicriviroc/FTC
  • dolutegravir/rilpivirine
  • doravirine/TDF/3TC
  • raltegravir formulation for once-daily dosing

Progressing: Generally in Active Phase I or Phase II

  • GS-9883
  • BMS-955176
  • cabotegravir (oral formulation)
  • long-acting injections:
    • cabotegravir LA
    • rilpivirine LA
    • co-formulated cabotegravir/rilpivirine LA
  • monoclonal antibodies (mAbs):
    • ibalizumab
    • PRO 140
    • other mAbs

Compounds with little or no progress irrespective of development phase include an entry inhibitor (albuvirtide) and the NRTIs apricitabine, censavudine, and EFdA.

Other F/TAF Co-formulations

In addition to developing E/C/F/TAF and F/TAF, Gilead is collaborating with Janssen on FDCs of darunavir/cobicistat/FTC/TAF (D/C/F/TAF) and rilpivirine/FTC/TAF (R/F/TAF) [Editor’s note: an NDA supporting the approval of R/F/TAF was filed with the FDA at press time.].

Forty-eight-week data from a randomized, double-blind, placebo-controlled phase II study in ART-naive adults with eGFR >70 mL/min were published in April 2015.38 The study randomized 153 patients (2:1) to receive the D/C/F/TAF co-formulation or separate darunavir and cobicistat plus TDF/FTC.

The primary endpoint of virological suppression (<50 copies/mL) at week 24 was reported for 75% in the D/C/F/TAF group compared with 74% in the D/C/F/TDF group (weighted difference: 3.3% [95% CI: −11.4% to 18.1%]). Though this study was not sufficiently powered for noninferiority, the standard non-inferiority margin of −12% was prespecified by the investigators (i.e., the lower boundary of the weighted difference of the CI was >−12%).

At week 48, viral-load suppression rates were 77% versus 84%, respectively (weighted difference: −6.2 [95% CI: −19.9 to 7.4], P = 0.35). This difference, the authors note, was partly due to a higher rate of loss to follow-up in the D/C/F/TAF group (6.8%) compared with the D/C/F/TDF group (2%), though for reasons other than virological failure.

Bone and renal markers suggested potential benefits for TAF. At 48 weeks, reductions in bone mineral density in both spine and hip were significantly less pronounced in the D/C/F/TAF group: −1.57% versus −3.62% (P = 0.003) and −0.84% versus −3.82% (P < 0.001), respectively. Median reduction in eGFR was also less pronounced in the D/C/F/TAF group: −2.9% versus −10.6% (P = 0.017).

An active-controlled phase III switch study of 420 patients on a boosted PI (atazanavir, darunavir, or lopinavir) plus TDF/TFC that will randomize participants to either change to the D/C/F/TAF FDC or remain on the multitablet combination is listed but was not yet enrolling as we went to press.39 At week 48, all participants will have the option to use the FDC.

With regard to R/F/TAF, Gilead is conducting two randomized placebo-controlled phase III switch studies in people with no history of drug resistance. Both studies evaluate switching to the new FDC following more than six months of virologic suppression with either efavirenz/FTC/TDF (study 311-1160) or rilpivirine/FTC/TDF (study 311-1216) compared with remaining on these two approved FDCs.40,41

Because TAF can reach intracellular concentrations that are substantially higher than those associated with TDF, it is active against virus with the TDF-associated K65R mutation, the multinucleoside/nucleotide T69S and Q151M mutations, and up to three thymidine analogue mutations (TAMs).42 Gilead is evaluating E/C/F/TAF in treatment-experienced (including TDF-experienced) patients. Further development of resistance, even in the presence of K65R, appears to be limited in vitro.43

Study 292-0117 is evaluating the efficacy of TAF versus placebo added to a failing regimen for 10 days, followed by treatment with atazanavir plus E/C/F/TAF.44 The primary endpoint is viral-load reduction of >0.5 log copies/mL at day 10. The trial will recruit 100 participants with detectable viral loads (between 500 copies/mL and 100,000 copies/mL) on current treatment with NRTI resistance. This is defined either as one to three TAMs, or as K65R plus M184V, and at least one major NNRTI or PI mutation.

A clinical trial is also looking at a regimen of E/C/F/TAF plus darunavir (study 292-0119) as a switch strategy in treatment-experienced patients who are stable on their current antiretroviral therapy.45 However, new data suggest that darunavir trough concentrations are reduced by approximately 80% – to subtherapeutic levels (median trough: 0.273 mg/L [interquartile range: 0.164–0.501] vs. historical population median of 1.36 mg/L with once-daily 800 mg darunavir plus 100 mg ritonavir) – when combined with E/C/F/TDF.46

Participants must have a history of at least two previous antiretroviral regimens, along with a history of resistance to at least two different drug classes, and be virally suppressed on a regimen containing darunavir. Entry criteria require current use of raltegravir, elvitegravir, or dolutegravir (50 mg once daily, but not twice daily) or documentation showing no evidence of resistance to these INSTIs. The cost-effectiveness analysis from this study, particularly in light of the questionable added benefit of darunavir, will be worth noting.

Although they are not yet in human studies, matchstick-sized TAF implants notably produced sustained drug levels for over a month in a beagle study in the context of use for pre-exposure prophylaxis (PrEP).47

Doravirine (MK-1439)

Doravirine is a once-daily NNRTI being developed by Merck that can be taken with or without food. It has in vitro activity against common NNRTI resistance mutations (K103N, Y181C, G190A, E101K, E138K, and K103N/Y181C) and selects for distinct mutations in vitro (V106A, F227L, and L234I), suggesting limited cross-resistance to rilpivirine or etravirine.48 Additional analyses noted that mutant viruses selected by doravirine are susceptible to rilpivirine and efavirenz, and mutants selected by rilpivirine and efavirenz are susceptible to doravirine.

Doravirine is primarily metabolized by CYP3A4 but is neither an inducer nor an inhibitor. In a seven-day monotherapy evaluation using 25 mg and 200 mg once-daily oral dosing, doravirine produced a median reduction in viral load of 1.3 log copies/mL.

Based on 24-week primary efficacy results from the phase IIb P007 doravirine dose-finding study (using 25 mg, 50 mg, 100 mg, and 200 mg) in 208 treatment-naive patients compared with standard dose efavirenz, the 100 mg dose was selected for phase III studies. This was reported in the 2014 Pipeline Report.

From week 36, an additional 132 people were randomized to doravirine 100 mg or efavirenz, and the original participants all switched to the 100 mg dose. TDF and FTC were used as background NRTIs throughout. Week 48 results from this complicated group were presented at Glasgow 2014, together with a week-8 analysis of central nervous system (CNS) side effects from the 100 mg doravirine versus combined efavirenz groups.49

At baseline, median CD4 count and viral load for all participants was approximately 400 cells/mm3 (range: 90–1,100) and 4.6 log copies/mL (range: 2.6–6.7). Around 10% had CD4 counts <200 cells/mm3, and 30% had viral loads higher than 100,000 copies/mL.

Efficacy and safety results at week 48 were broadly similar to those at week 24. By intent-to-treat analysis (where noncompletion equaled failure), suppression to <40 copies/mL was achieved by 72%, 72%, 76%, and 83% in the 25 mg, 50 mg, 100 mg, and 200 mg doravirine groups (76% combined) versus 71% in the efavirenz arm. Using a 200 copies/mL cutoff, rates were 85% (doravirine combined) versus 79%.

The most common adverse events in the combined doravirine and efavirenz groups were abnormal dreams (10.2% vs. 9.5%), nausea (7.8% vs. 2.4%), fatigue (7.2% vs. 4.8%), diarrhea (4.8% vs. 9.5%), and dizziness (3.0% vs. 23.8%), and they were generally mild to moderate. The rate of discontinuation due to drug-related adverse events was twice as high in the combined efavirenz groups compared with the efavirenz group: 2.4% vs. 4.8%.

Week-8 CNS tolerability data for 216 participants randomized to 100 mg doravirine or efavirenz reported at least one CNS-related adverse event in 22.2% of the doravirine group compared with 43.5% of the efavirenz group (difference: −21.3% [95% CI: −33.2 to −8.8]; P < 0.001). The most common CNS adverse events were dizziness (9.3% vs. 27.8%), insomnia (6.5% vs. 2.8%), abnormal dreams (5.6% vs. 16.7%), and nightmares (5.6% vs. 8.3%); all doravirine compared with efavirenz.

A phase III study comparing doravirine to darunavir/ritonavir in treatment-naive patients started in late 2014 and includes sites in the United States, Canada, Puerto Rico, and Europe.50

Additional phase III studies using the FDC of doravirine plus generic TDF and 3TC are due to start in mid-2015, including one in treatment-naive patients with efavirenz as a control and a second in patients virally suppressed on PI/ritonavir-based combinations. Final results are likely to coincide with TDF’s patent expiration in 2017.51,52


Fostemsavir (BMS-663068) is a prodrug of the attachment inhibitor BMS-626529 that produced median viral-load reductions of 0.7 to 1.5 log copies/mL after 7 days of monotherapy. It is active against both CCR5- and CXCR4-tropic HIV, but not subtype AE and group O.53,54 Fostemsavir is an oral twice-daily drug that binds directly to gp120, causing conformational changes that block attachment to the CD4 receptor.

Forty-eight-week data from an international phase IIb dose-ranging study were reported at CROI 2015.55 Treatment-experienced participants, all of whom had virus susceptible to raltegravir, TDF, and atazanavir, were randomized to receive fostemsavir at doses of 400 mg twice daily, 800 mg twice daily, 600 mg once daily, or 1,200 mg once daily, compared with ritonavir-boosted atazanavir, all in combination with raltegravir and TDF. Sensitivity to BMS-626529 was an entry requirement (IC50 <100 nM). Approximately 5% of study participants did not meet this criterion, and the PhenoSense Entry Assay did not provide a result for 26% of screening samples.

A total of 251 participants were treated. Median age at baseline was 39 years; 60% were male and 38% were white. The median pretreatment viral load was 4.85 log copies/mL (43% had viral loads >100,000 copies/mL), and CD4 count was 230 cells/mm3 (38% with <200 CD4 cells/mm3).

At week 48 in the modified intent-to-treat analysis, viral response rates to <50 copies/mL were comparable across all groups regardless of gender, age, and race: between 61% and 82% in the fostemsavir group and 71% in the atazanavir group. Response rates in participants with baseline viral loads >100,000 copies/mL were lower in all arms, including the atazanavir/ritonavir control group.

CD4 count gains were similar across all groups, with mean increases ranging from 141 to 199 cells/mm3 by week 48.

Seven participants discontinued treatment due to adverse events (two in the atazanavir group, five in the different fostemsavir groups), but none of the discontinuations was believed to be directly related to the study drugs used. Abdominal pain, nausea, and headache were among the most common side effects, though most occurred in the atazanavir group. Similarly, elevations in bilirubin occurred in 29/51 (58%) of participants in the atazanavir group compared with no cases of hyperbilirubinemia or jaundice in the fostemsavir groups. Laboratory abnormalities were uncommon among those receiving fostemsavir, with no clinically relevant changes in total cholesterol, LDL, or triglycerides.

A phase III trial of fostemsavir in treatment-experienced patients started in February (study AI438-047).56 Approximately 410 participants will be enrolled. Entry criteria include detectable viral load of >400 copies/mL on current ART and resistance, intolerance, or contraindications to drugs in at least three classes. Participants must be taking at least one, but no more than two, active approved drugs to be eligible for the randomized, placebo-controlled eight-day monotherapy arm of the study. Optimized background therapy is added after day 8, with all participants receiving open-label fostemsavir (600 mg twice daily) for at least 48 weeks.

Participants who are not taking any active approved drugs can enroll in an open-label cohort. This arm includes the option of using the experimental monoclonal antibody ibalizumab to prevent functional monotherapy, although ibalizumab has to be procured by the individual participant and is not provided as part of the study. (See the discussion below on the FDA treatment investigational new drug [IND] allowance of ibalizumab.)

The fusion inhibitor enfuvirtide (T-20, Fuzeon) can be used in both the randomized and nonrandomized arms to help construct the most viable combination.

An astonishing 137 clinical trial sites in Argentina, Australia, Belgium, Brazil, Canada, Chile, Colombia, France, Ireland, Italy, the Netherlands, Peru, Poland, Portugal, Puerto Rico, Romania, Russia, Spain, Taiwan, the United Kingdom, and the United States have been contracted to ensure adequate and prompt enrollment.

Cenicriviroc (Previously TBR-652)

Cenicriviroc is a CCR5 inhibitor that produced median viral-load reductions of 1.7 log following 10 days of monotherapy in a phase I study presented at CROI in 2010. It is also active against CCR2. In a randomized, double-blind, placebo-controlled phase IIb study comparing cenicriviroc with efavirenz in treatment-naive patients, all with background TDF/FTC, viral suppression to <50 copies/mL at week 48 was 68%, 64%, and 50% in the 100 mg, 200 mg, and efavirenz groups, respectively, when reported in 2013.57 No new clinical data have been reported since then.

Tobira’s phase III program was due to evaluate a co-formulation tablet containing 200 mg cenicriviroc and 300 mg 3TC, but no new clinical trials have been announced.

Cenicriviroc may also be active against HIV-2 in CCR5-tropic patients.58 It is also being studied as a potential treatment for mild-to-moderate HIV-associated neurocognitive decline, based on the hypothesis that dual CCR5 and CCR2 blockade will lead to reductions in monocyte activation, a potential inflammation-related driver of neurocognitive impairment.59 CCR5 and CCR2 blockade may also be associated with antifibrotic activity; hence, cenicriviroc is currently being evaluated as a potential treatment for nonalcoholic steatohepatitis (NASH).60

Raltegravir (Once-Daily Formulation)

Once-daily dosing of Merck’s INSTI was not approved after the QDMRK trial, which failed to show that once-daily dosing of raltegravir (800 mg) was noninferior to twice-daily dosing (400 mg) for first-line therapy.61

Several newer formulations have led to a 600 mg version (total daily dose 1,200 mg)62 that is currently being compared in a phase III randomized, double-blind noninferiority study (onceMRK) with the approved twice-daily formulation in treatment-naive participants. Primary endpoint results at 48 weeks from this 96-week study are expected in early 2016.63

Clinical results, not just pharmacokinetics (PK)/pharmacodynamics data, appear to be a requirement of once-daily dosing approval.

BMS-955176 (BMS-176)

BMS-176 is a second-generation maturation inhibitor that targets the final stage of HIV Gag processing and inhibits release of the fully formed capsid. Maturation inhibitors are a new class of antiretrovirals that may have an important role for people with resistance to currently approved drugs.

The first-generation maturation inhibitor bevirimat (PA-457) was discontinued in June 2010 due to limited antiviral activity against HIV with common (in 30%–40% of treatment-naive patients) polymorphisms at positions 369, 370, or 371 in Gag.

BMS’s compound has greater potency and coverage of Gag polymorphisms compared with bevirimat,64 along with a half-life supportive of once-daily dosing and no significant safety issues identified in phase I studies.65

Preliminary results from a 10-day dose-ranging monotherapy study of BMS-176 were reported at CROI 2015.65 BMS-176 doses of 5, 10, 20, 80, and 120 mg were evaluated in six dosing groups, each composed of 10 HIV-positive, treatment-naive participants (two in each group received matching placebo). All but one participant were men; only three were nonwhite.

At each of the three higher doses, comparable reductions of −1.4 logs were reported at day 10, with HIV RNA declines sustained for approximately a week after the drug was discontinued. Maximum median reduction in viral load was 1.7 log copies/mL in the 40 mg arm. Results were broadly similar for each group irrespective of baseline polymorphisms.

Side effects reported by >5% of participants included headache, abnormal dreams, night sweats, and diarrhea, but they were broadly similar between active drug and placebo recipients with no treatment discontinuations. No serious side effects or laboratory abnormalities were reported other than two single cases of transient grade 3 neutropenia (one each in the 80 mg and 120 mg groups).

Clinical trials currently planned or under way include a food effect trial, a second dose-finding study further evaluating 60 and 120 mg BMS-176, and a phase IIb study evaluating the safety and efficacy of the maturation inhibitor combined with atazanavir (either with or without ritonavir) and dolutegravir in 200 treatment-experienced participants.66,67,68


GS-9883 is a second-generation INSTI in development by Gilead that, unlike elvitegravir, does not require PK boosting.

A phase Ib dose-ranging study using doses from 5 mg to 100 mg for 10 days of monotherapy in treatment-naive HIV-positive participants has been completed; results are expected shortly.69

A phase II trial comparing GS-9883 with dolutegravir in approximately 75 HIV-positive, treatment-naive participants, with all participants using separate background FTC/TAF, is currently under way in the United States.70


Cabotegravir (formerly S/GSK-744) is an INSTI and an analogue of dolutegravir. It is being developed as an oral tablet for once-daily dosing and a long-acting parenteral administration formulation (cabotegravir LA).

Cabotegravir has a low nanomolar potency to treat wild-type HIV infection, with a >2-log impact on viral load after 10 days of monotherapy. It has activity against a broad range of single integrase-associated drug mutations that can overcome early resistance to raltegravir and elvitegravir, but it loses significant sensitivity in the presence of E138K/Q148K and Q148R/N155H complexes. Also similarly to dolutegravir, it has a high barrier to resistance that makes resistance in integrase-naive patients rare. The half-life of the oral drug is >40 hours, easily allowing once-daily dosing, and is >40 days for the long-acting formulation, allowing monthly or quarterly injections depending on dose and formulation.71

Phase I and IIa studies reported low PK variability, generally good tolerability, and limited drug interactions. Injection-site reactions were common with the long-acting formulations. The current intramuscular (IM) formulation requires two 2 mL gluteal injections (four injections for the initial loading dose and two injections subsequently). This was associated with moderate pain in 20% of participants lasting, on average, five days (range: 1–30).72,73

Clinical efficacy and safety of cabotegravir come from a phase II dose-ranging study that used oral cabotegravir and oral rilpivirine as two-drug maintenance therapy, with 96-week data presented at CROI 2015.74

The LATTE study enrolled 243 treatment-naive HIV-positive participants, mostly in early infection. Median baseline viral load and CD4 count were 20,000 copies/mL (14% >100,000) and 410 cells/mm3 (<5% were <200). For the 24-week induction phase, participants were randomized to cabotegravir (10, 30, or 60 mg) or efavirenz, plus investigator choice of TDF/FTC or abacavir/3TC. If viral loads were <50 copies/mL at week 20, then those receiving cabotegravir substituted their NRTIs for 25 mg oral rilpivirine at week 24 for a further 72 weeks of maintenance therapy. The efavirenz control arm continued the NRTI backbone.

At week 24, viral load was <50 copies/mL in 87% of those in the combined cabotegravir/rilpivirine groups compared with 74% in the efavirenz group. In the week-96 analysis, which included those who did and did not meet the maintenance therapy requirement, 76% of those in the cabotegravir/rilpivirine groups, compared with 63% of those in the efavirenz group, had viral loads of <50 copies/mL. The difference between doses – 68%, 75%, and 84% in the 10 mg, 30 mg, and 60 mg groups – was related to nonvirological discontinuations.

Limiting the analysis to the 47 participants in the efavirenz group and the 160 in the cabotegravir/rilpivirine groups who met the viral-load criteria for continuing in the maintenance phase of the study, 86% in the cabotegravir/rilpivirine arm, compared with 83% of the efavirenz arm, had viral loads <50 copies/mL at week 96. The rate of virological failure in the maintenance population was 3% in the combined cabotegravir groups, compared with 4% in the efavirenz arm.

Three participants originally randomized to the 10 mg cabotegravir group developed treatment-emergent NNRTI mutations during the study; one also developed an INSTI mutation.

Participants were more likely to withdraw from the study due to adverse events in the efavirenz group compared with the combined cabotegravir groups (15% vs. 4%, respectively), usually before the start of the maintenance therapy phase of the trial. CNS effects were more commonly seen in the efavirenz arm. Headache was more common in the cabotegravir groups. Most adverse events were mild to moderate in intensity.

The 30 mg dose of cabotegravir was selected for further development of the oral formulation. A study evaluating the bioavailability of different 30 mg tablet formulations is now under way.75

Long-Acting Formulations: Cabotegravir LA and Rilpivirine LA

The availability of both cabotegravir and rilpivirine in long-acting injectable formulations led to a development program that will co-formulate both drugs as a monthly IM injection.

Long-acting drug formulations allowing monthly or less frequent dosing have the potential to improve clinical outcomes in all patient groups where adherence continues to be difficult. For this reason, many patient groups find long-acting formulations preferable to having to take daily pills. These slow-release formulations might have better tolerability, especially reduced gastrointestinal and other side effects.

Additionally, they may be cheaper than oral formulations to produce, given that they use less API and packaging, generate fewer distribution costs, and could potentially help overcome a key global concern of stock-outs in low-income countries.

The INSTI cabotegravir (S/GSK1265744) and the NNRTI rilpivirine are already being combined in phase II/III clinical trials. They employ nanoformulation technologies to overcome the bioavailability, water solubility, and stability weaknesses of oral antiretrovirals. These formulations also have an exciting potential for use as PrEP (see Preventive Technologies for details).

Challenges remain, however:

  • Oral lead-in dosing is currently necessary to safeguard against serious adverse events, including hypersensitivity reactions.
  • A minimum period with undetectable viral load in the induction phase might be important prior to the dual-therapy maintenance therapy.
  • It is not known how to manage drug interactions after long-acting antiretrovirals have been given (e.g., if rifampin-inclusive treatment is necessary for tuberculosis if it is diagnosed later).
  • It is not known how to manage the PK “tail” at the end of the dose with compounds that have such extremely long half-lives. Unless treatment is switched to an oral combination, vulnerability to drug resistance to both INSTIs and NNRTIs is high when drug concentrations fall below their inhibitory concentrations. This raises concerns relating to missed injections, whether from adherence or supply issues.
  • Patient acceptability may be low if the volume of injections for both drugs is high, if the drugs are given by multiple injections, or if monthly clinic visits are necessary to receive the injections.

A phase IIb maintenance therapy trial employing the long-acting injectable formulations of cabotegravir and rilpivirine is now under way.76 The study will consist of three phases: an induction phase, a maintenance phase, and an extension phase. Importantly, there is also a long-term follow-up phase for participants who withdraw from the study and have received at least one dose of cabotegravir LA and rilpivirine LA, in order to study and ensure adequate follow-up during the PK tail period following administration of both long-acting drugs.

In the induction phase, participants will receive oral cabotegravir (30 mg) plus abacavir/3TC once daily for 20 weeks and will then add oral rilpivirine for an additional four weeks. In the maintenance phase, beginning at week 24, eligible participants will be randomized 2:2:1 to one of the following treatment arms:

  • IM regimen of cabotegravir LA (400 mg) + rilpivirine LA (600 mg) every four weeks for 96 weeks (the first dosing clinic visit will require loading doses of two 400 mg cabotegravir LA injections and one 600 mg rilpivirine injection);
  • IM regimen of cabotegravir LA (600 mg) + rilpivirine LA (900 mg) every eight weeks for 96 weeks (the first dosing clinic visit will require loading doses of two 400 mg cabotegravir LA injections and one 900 mg LA injection; the second dosing clinic visit, four weeks later, will require an additional 600 mg loading dose of cabotegravir LA); or
  • continuation of the oral induction phase regimen of cabotegravir plus abacavir/3TC once daily for 96 weeks (or 104 weeks if continuing on to the extension period).

The trial is now fully enrolled with 265 participants.

Long-Acting Rilpivirine

Rilpivirine has undergone several PK, safety, and efficacy evaluations, which include phase I studies exploring oral and long-acting parenteral coadministration with cabotegravir.72

ViiV Healthcare, in collaboration with Janssen, is primarily conducting the clinical development of long-acting rilpivirine for therapeutic purposes.


Based in part on the encouraging data from the LATTE study, ViiV and Janssen are developing an FDC containing standard doses of dolutegravir (50 mg) and rilpivirine (25 mg) as a single-tablet, two-drug, NRTI-free maintenance regimen.77 Should the FDC prove durable and safe, its approval and availability may serve as a stopgap until the long-acting formulations of cabotegravir and rilpivirine are approved, as an oral maintenance therapy alternative to long-acting cabotegravir/rilpivirine injections, or as an oral option to be initiated should long-acting cabotegravir/rilpivirine injections need to be discontinued.

A number of clinical trials of this oral maintenance regimen are planned or now under way. These include an FDC formulation study and three switch clinical trials.78,79,80,81

Censavudine (OBP-001, formerly festinavir/BMS-986001)

This molecule has a similar structure to the NRTI d4T (stavudine) but with in vitro data that suggested it may have none of d4T’s problematic side effects.

Results from a phase IIb study presented at the Interscience Conference of Antimicrobial Agents and Chemotherapy in 2014 comparing once-daily BMS-986001 with TDF (with background efavirenz plus 3TC) reported similar efficacy at weeks 24 and 48 with higher doses, but with higher rates of drug resistance in people experiencing virological failure.82 Slight differences in bone changes and increases in peripheral fat were reported with BMS-986001, but no statistical analysis was performed to support this.83

A potential role for censavudine in treating HIV-2 was suggested in a poster at the 2015 International Drug Resistance Workshop that reported greater in vitro activity against HIV-2 compared with HIV-1 and the ability of the drug to overcome key NRTI resistance mutations.84

Despite this, BMS has since dropped its option to develop the compound, and the rights have reverted to Oncolys.

Monoclonal Antibodies

Research into the potential therapeutic role for monoclonal antibodies in management of HIV has been ongoing for well over a decade. Although progress was slow with the earliest compounds, more recent discoveries of a number of more potent and more broadly neutralizing monoclonal antibodies (bNAbs) has led to greater optimism that they might play an important role in both treatment and cure research.

A meeting cosponsored by the U.S. National Institute of Allergy and Infectious Diseases (NIAID) and the Bill & Melinda Gates Foundation in June 2015 brought together more than 140 scientists, researchers, industry, regulators, advocates, and funders to review the current state of this research and to encourage collaborations that would bring advances more rapidly to clinical studies.

In addition to discussing ibalizumab and PRO140, discussed separately below, the meeting reported on more recently developed compounds, including VRC01, which is being developed by the U.S. National Institutes of Health (NIH) Vaccine Research Center, and 3BNC117, which is being developed by the Rockefeller University with support from the NIH. Both are bNAbs with activity against many diverse HIV strains. In addition to their possible use for therapeutic purposes, they are being eyed for their prevention potential as passive immunization and their curative potential in combination with latency-reversing drugs (for more, see Preventive Technologies and Research Toward a Cure and Immune-Based and Gene Therapies).

In a recently published study, 12 HIV-negative and 17 HIV-positive individuals received single infusions of 1, 3, 10, or 30 mg/kg of 3BNC117.85 The infusions were well tolerated, and the HIV-positive participants in the two highest dose groups, particularly the eight individuals in the 30 mg/kg group, experienced viral-load reductions between 0.8 and 2.5 log copies/mL, which persisted for at least 28 days in some cases. Baseline resistance to 3BNC117 was documented in one individual, as well as evolving resistance to the antibody among some participants in the lowest dose groups.

Indeed, a key theme from the Bethesda meeting was the need for future research to use multiple bNAbs from an extensive panel of isolates in combination to ensure sufficient coverage and to minimize the risk of resistance, which paralleled learning from the experience of early ART.

Ibalizumab (TMB-355)

Ibalizumab (TMB-355) is a monoclonal antibody that binds to CD4 and blocks HIV entry post-attachment. It is being developed, albeit slowly, by TaiMed Biologics and was recently granted orphan designation by the FDA due to its limited but important treatment potential. It has been studied primarily as an intravenous (IV) formulation and is being looked at principally as a regimen component for people with cross-class-resistant HIV.

In phase I and II studies completed to date, there were mean viral-load reductions of −0.95 to −1.96, with no severe drug-related adverse events reported among the 247 participants who received the drug via IV administration.

No additional phase II or phase III treatment protocols have been announced other than an ongoing one (investigator-sponsored) that allows participants in the phase IIb clinical trial to continue received ibalizumab with optimized background therapy.86 For treatment-experienced patients requiring ibalizumab to construct a viable or tolerable antiretroviral regimen, TaiMed is providing the IV formulation of the drug through a treatment IND program, which requires each patient and his or her health care provider to apply for access to the drug through regulatory agencies.87 Additionally, in response to advocates’ requests, BMS has agreed to allow heavily treatment-experienced patients enrolled in the nonrandomized arm of its phase III evaluation of the attachment inhibitor fostemsavir to use ibalizumab to help optimize treatment outcomes.56

Ibalizumab has been reformulated for subcutaneous administration, with encouraging safety and PK data reported in September 2014.88

PRO 140, originally developed by Progenics and now owned by CytoDyn, is a monoclonal antibody targeting CCR5. Phase I and phase II studies exploring single-dose intravenous infusions of PRO 140 at doses of 5 mg/kg or 10 mg/kg reported mean maximum viral-load reductions of 1.8 log copies/mL in the absence of other antiretrovirals.89,90 Weekly (162 mg and 324 mg) and biweekly (324 mg) subcutaneous administration have also been evaluated, yielding mean viral-load reductions of 1.37 log to 1.65 log copies/mL and no serious adverse events.91

Though no new PRO 140 data have been reported since 2010, phase II studies are planned or under way. These include an ongoing evaluation of a treatment substitution strategy that calls for alternating between daily oral dosing of standard antiretrovirals and PRO 140 administration (i.e., three months of daily oral antiretroviral treatment followed by three months of weekly injections of PRO 140, followed by a return to daily oral antiretrovirals), as well as a study of subcutaneous injections of PRO 140 added to an optimized antiretroviral regimen for HIV-positive injection drug users with viral rebound and documented poor adherence that was announced in 2011 and has yet to open to enrollment.92,93


The antiretroviral drug pipeline remains robust, with significant advancements of several compounds now in late-stage development and the entry of new compounds with potential for both treatment-experienced and treatment-naive populations. TAF continues to show well in clinical trials, demonstrating its promise as a new version of a drug that remains a backbone of treatment regimens throughout the world; doravirine is now in phase III evaluations as a generic-backed co-formulated, single-tablet regimen; and data continue to support the exploration of long-acting dual-drug injectable regimens as maintenance therapy. For treatment-experienced individuals, the advancement of fostemsavir – particularly into a highly ambitious, multinational phase III clinical trial with an open-label arm for patients in desperate need of new treatment options – and the entrance of BMS-955176 are encouraging, as is the orphan designation for ibalizumab.

This is not to say that all pipeline contenders are advancing in a seamless fashion, nor are their launch and commercial successes yet being viewed against the backdrop of increasingly perilous cost and access considerations.


  • Manufacturers must commit to drug prices required to achieve cost-contained HIV care and service delivery in high-income countries.
  • Manufacturers developing new oral drugs are strongly encouraged to follow the emerging trend of evaluating co-formulations with historically potent and safe generic antiretrovirals, notably TDF and 3TC. However, these fixed-dose combinations must be priced accordingly.
  • Gilead Sciences should commit to a more robust research program for TAF that covers three main concerns:
    1. Head-to-head comparisons of TAF- versus TDF-inclusive regimens, including those with drugs that do not require boosting, in treatment-naive individuals (i.e., not just switch studies).
    2. Evaluations of lower-dose TAF (e.g., 2 mg and 10 mg in cobicistat-boosted and cobicistat-unboosted regimens, respectively), in light of data suggesting that the increased intracellular concentrations associated with 10 and 25 mg dosing do not confer potency advantages compared with TDF in treatment-naive populations. This may have potential for further improved safety and API requirements.
    3. Collaboration with the FDA and other regulatory agencies to fully validate intracellular, versus blood plasma, drug concentrations as a bona fide PK marker. This is key to supporting bioequivalence data requirements for generic co-formulations in low-income countries (e.g., fixed-dose combinations containing 3TC instead of FTC).
  • Long-acting antiretrovirals for parenteral administration continue to hold tremendous promise for treatment and prevention. Though safety and efficacy trials should be prioritized, research to more fully evaluate potential implementation challenges of these drugs – such as dosing and clinical follow-up acceptability and feasibility evaluations – should be planned.
  • The development of new drugs for treatment of cross-class-resistant HIV should remain a priority. It is very encouraging to see progress in this area. For drugs with limited indications, including those without clear marketing potential for treatment-naive individuals, the Orphan Drug Designation program should be explored and engaged.
  • Manufacturers should continue to closely collaborate with, and invest heavily in, evidence-based research, implementation science, policy advocacy, and service delivery aimed at improving HIV diagnosis and clinical care engagement rates. Their efforts should aim to maximize virological suppression rates required to improve disease-free mortality and prevent ongoing transmission of the virus.


BHIVA: British HIV Association
CROI: Conference on Retroviruses and Opportunistic Infections
EACS: European Conference on AIDS
IAC: International AIDS Conference (World AIDS Conference)
IAS: IAS Conference on HIV Pathogenesis, Treatment and Prevention
ICAAC: Interscience Conference on Antimicrobial Agents and Chemotherapy

Unless noted otherwise, all links were accessed on May 13, 2015.

  1. Insight. 10th review by the data and safety monitoring board. INSIGHT [Internet]. 2015 May 15.
  2. Collins S. Breaking news: what do the START results mean for HIV positive people. HIV i-Base [Internet]. 27 May 2015.
  3. Hill A, Pozniak A, Simmons B. No difference in risk of virological failure between antiretroviral treatments using co-formulated versus individual drugs: meta-analysis of 9 randomised trials in 2,568 patients (Abstract O-10). 21st Annual BHIVA Conference; 2015 April 21–24; Brighton, United Kingdom.
  4. Hill A. Generics: the facts. 21st Annual BHIVA Conference (invited lecture). 2015 April 21–24, Brighton, UK.
  5. ViiV Healthcare (Press Release). ViiV Healthcare receives FDA approval for Triumeq. 2014 August 22.
  6. ViiV Healthcare (Press Release). ViiV Healthcare receives EU marketing authorization for Tirumeq. 2014 September 3.
  7. Weller S, Chen S, Borland J, et al. Bioequivalence of a dolutegravir, abacavir and lamivudine fixed-dose combination tablet and the effect of food. J Acquir Immun Defic Syndr. 2014 Aug 1;66(4):393–8.,_Abacavir_and.97920.aspx_Abacavir_and.97920.aspx.
  8. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents (U.S.). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Rockville, MD: Department of Health and Human Services (U.S.). 2015 April 8.
  9. Panel de expertso de GeSIDA y Plan Nacional sobre el Sida (Spain). Documento de consenso de GeSIDA/Plan Nacional sobre el Sida respect al tratamiento antiretroviral en adultos con infeccion por el virus de la immunodeficiencia humana. Madrid: Ministerio de Sanidad, Servicios Sociales e Igualidad (Spain). 2015 January.
  10. Janssen, Inc. (Press Release). Prezcobix now available for Canadians living with HIV. 2014 September 17.
  11. Janssen, Inc. (Press Release). European Commission approves Rezolsta, a new once-daily, fixed-dose HIV therapy combining darunavir and cobicistat. 2015 November 25.
  12. Janssen Therapeutics (Press Release). Prezcobix (darunavir/cobicistat) approved in the U.S. for the treatment of adults living with HIV. 2015 January 29.
  13. Kakuda TN, Van De Casteele T, Petrovic R, et al. Bioequivalence of a darunavir/cobicistat fixed-dose combination tablet versus single agents and food effect in healthy volunteers. Antivir Ther. 2014;19(6):597–606.
  14. Tashima K, Crofoot G, Tomaska FL, et al. Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a phase IIIb, open-label single-arm trial. AIDS Res Ther. 2014;11:39. doi: 10.1186/1742-6405-11-39.
  15. Bristol-Myers Squibb (Press Release). U.S. Food and Drug Administration approves Bristol-Myers Squibb’s Evotaz (atazanavir and cobicistat) for the treatment of HIV-1 infection in adults. 2015 January 29.
  16. Sevinsky H, Tao X, Wang R, et al. A randomized trial in healthy subjects to assesses the bioequivalence of an atazanavir/cobicistat fixed-dose combination tablet versus administration as separate agents. Antivir Ther. 2014 Oct 31.
  17. Lennox JL, Landovitz RJ, Ribaudo HJ, et al. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naïve volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med. 2014 Oct 7;(161(7):461–71.
  18. Food and Drug Administration (U.S.). Dutrebis approved, though not commercially marketed in US at this time [Internet]. 2015 February 6.
  19. Schwind, John (Merck, Upper Gwynedd, PA). E-mail with: Tim Horn (Treatment Action Group, New York, NY). 2015 April 17.
  20. Merck. Highlights of prescribing information for Detrubis (lamivudine and raltegravir). 2015 February.
  21. Food and Drug Administration (U.S.). Approval of Tybost (cobicistat) 150 mg tablets. HIV/AIDS Update [Internet]. 2014 September 25.
  22. Food and Drug Administration (U.S.). Approval of Vitekta. HIV/AIDS Update [Internet]. 2014 September 25.
  23. Gilead Sciences (Press Release). Gilead submits new drug application to U.S. Food and Drug Administration for tenofovir alafenamide (TAF)-based single tablet regimen for HIV. 2014 November 6.
  24. Gilead Sciences (Press Release). Gilead submits new drug application to U.S. Food and Drug Administration for fixed-dose combination of emtricitabine/tenofovir alafenamide for HIV treatment. 2015 April 7.
  25. Markowitz M, Zolopa A, Squares K, et al. Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults. J Animicrob Chemother. 2014 May;69(5):1362–9.
  26. Ruane P, DeJesus E, Berger D, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr. 2013 Aug1;63(4):449–55.
  27. Custodio J, Garner W, Callebaut C, et al. The pharmacokinetics of tenofovir and tenofovir diphosphate following administration of tenofovir alafenamide versus tenofovir disoproxil fumarate (Abstract 6). 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, 2015 May 26–28, Washington, D.C.
  28. Eisenberg EJ, He GX, Lee WA. Metabolism of GS-7340, a novel phenyl monophosphoramidate intracellular prodrug of PMPA, in blood. Nucleosides Nucleotides Nucleic Acids. 2001 Apr–Jul;20(4–7):1091–8.
  29. Markowitz M, Zolopa A, Ruane P, et al. GS-7340 demonstrates greater declines in HIV-1 RNA than TDF during 14 days of monotherapy in HIV-1-infected subjects (Abstract 152LB). 18th CROI; 2011 February 27–March 4; Boston, MA.
  30. UNITAID and Medicines Patent Pool. Patents and licenses on antiretrovirals: A snapshot. 2014 April. Geneva: UNITAID.
  31. Wohl D, Pozniak A, Thompson M, et al. Tenofovir alafenamide (TAF) in a single-tablet regimen in initial HIV-1 therapy (Abstract 113LB). 22nd CROI; 2015 February 23–26; Seattle, WA.
  32. Sax PE, Saag MS, Yin MT, et al. Renal and bone safety of tenofovir alafenamide vs tenofovir disoproxil fumarate (Abstract 143LB). 22nd CROI; 2015 February 23–26; Seattle, WA.
  33. Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, conformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomized, double-blind, phase 3, non-inferiority trials. Lancet. 2015 Apr 15. doi: 10.1016/S0140-6736(15)60616-X. [Epub ahead of print]
  34. Post FA, Moyle GA, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1–infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr 2010; 55:49–57.,_Efficacy,.6.aspx.
  35. Pozniak A, Arribas J, Gupta SK, et al. Safety of tenofovir alafenamide in renal impairment (Abstract 795). 22nd CROI; 2015 February 23–26, Seattle, WA.
  36. Lawson E, Shao Y, Bennett S, et al. Week-24 data from a phase 3 clinical trial of E/C/F/TAF in HIV-infected adolescents (Abstract 953). 22nd CROI; 2015 February 23–26; Seattle, WA.
  37. McKeal, Ryan (Gilead Sciences, Foster City, CA). E-mail with: Tim Horn (Treatment Action Group, New York, NY). 2015 April 23.
  38. Mills A, Ortiz R, Crofoot G Jr, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in the first protease inhibitor-based single tablet regimen for initial HIV-1 therapy: A randomized phase 2 study. J Acquir Immune Defic Syndr. 2015 Aug 1;69(4):439-45. doi: 10.1097/QAI.0000000000000618.
  39. [Internet]. Bethesda (MD): National Library of Medicine (U.S.). 2000. Identifier NCT02269917, Study to evaluate efficacy of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) regimen versus boosted protease inhibitor (bPI) along with emtricitabine/tenofovir disoproxil fumarate (TDF/FTC) regimen in virologically-suppressed, HIV-1 infected participants. 2014 October 17.
  40. [Internet]. Bethesda (MD): National Library of Medicine (U.S.). 2000. Identifier NCT02345226, Study to evaluate switching from a regimen consisting of efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) fixed dose combination (FDC) to emtricitabine/rilpivirine/tenofovir alafenamide (FTC/RPV/TAF) FDC in virologically-suppressed, HIV-infected adults. 2015 January 19.
  41. [Internet]. Bethesda (MD): National Library of Medicine (U.S.). 2000. Identifier NCT02345252, Switch study to evaluate the safety and efficacy of emtricitabine/rilpivirine/tenofovir alafenamide (FTC/RPV/TAF) fixed dose combination (FDC) in HIV-1 positive adults who are virologically suppressed on emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF). 2015 January 19.
  42. Margot N, Liu Y, Babusis D, Miller MD, Callebaut C. Antiviral activity of tenofovir alafenamide (TAF) against major NRTI-resistant viruses: improvement over TDF/TFV is driven by higher TFV-DP loading in target cells (Abstract 23). International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies; 2013 June 4–8; Toronto, ON.
  43. Margot NA, Ram RR, Miller MD, et al. Limited evolution of tenofovir-resistant viruses after extended TAF resistance selection (Abstract 78). International Workshop on Antiviral Drug Resistance; 2014 June 3–7; Berlin. Antiviral Therapy 2014;19(Suppl 1):A118.
  44. [Internet]. Bethesda (MD): National Library of Medicine (U.S.). 2000. Identifier NCT01967940, Efficacy of tenofovir alafenamide versus placebo added to a failing regimen followed by treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide plus atazanavir in HIV-1 positive, antiretroviral treatment-experienced adults. 2014 April 10.
  45. [Internet]. Bethesda (MD): National Library of Medicine (U.S.). 2000. Identifier NCT01968551, Phase 3 open-label study to evaluate switching from optimized stable antiretroviral regimens containing darunavir to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) single tablet regimen (STR) plus darunavir (DRV) in treatment experienced HIV-1 positive patients. 2014 April 3.
  46. Ricard F, Wong A, Lebouche B, et al. Low darunavir concentrations in patients receiving Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) and darunavir once daily (Abstract 50). 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, 2015 May 26–28, Washington, D.C.
  47. Gunawardana M, Remedios-Chan M, Miller MS, et al. Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis. Antimicrob Agents Chemother. 2015 Apr 20. [Epub ahead of print]
  48. Lai MT, Feng M, Falgueryet JP, et al. In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2014;58(3):1652–63.
  49. Gatell JM, Morales-Ramirez JO, Hagins DP, et al. Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naïve HIV-positive patients. J Int AIDS Soc. 2014;17(Suppl 3):19532. doi: 10.7448/IAS.17.4.19532.
  50. [Internet]. Bethesda (MD): National Library of Medicine (U.S.). 2000. Identifier NCT02275780, Safety and efficacy of doravirine (MK-1439) in participants with human immunodeficiency virus 1 (HIV-1) (MK1439-018); 2014 October 23.
  51. [Internet]. Bethesda (MD): National Library of Medicine (U.S.). 2000. Identifier NCT02403674, Comparison of MK-1439A and Atripla in treatment-naïve human immunodeficiency virus (HIV)-infected participants (MK-1439A-021); 2015 March 26.
  52. [Internet]. Bethesda (MD): National Library of Medicine (U.S.). 2000. Identifier NCT02397096, Safety and efficacy of a switch to MK-1439A in human immunodeficiency virus (HIV-1)-infected participants virologically suppressed on a regimen of a ritonavir-boosted protease inhibitor and two nucleoside reverse transcriptase inhibitors (MK1439A-024) (DRIVE-SHAFT); 2015 March 18.
  53. Brown J, Chien C, Timmins P, et al. Compartmental absorption modeling and site of absorption studies to determine feasibility of an extended-release formulation of an HIV-1 attachment inhibitor phosphate ester prodrug. J Pharm Sci. 2013 Jun;102(6):1742–51.
  54. Nowicka-Sans B, Gong YF, McAuliffe B, et al. In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068. Antimicrob Agents Chemother. 2012 July;56(7):3498–507. doi: 10.1128/AAC.00426-12.
  55. Thompson M, Lalezari J, Kaplan R, et al. Attachment inhibitor prodrug BMS-663068 in ARV-experienced subjects: Week 48 analysis (Abstract 545). 22nd CROI; 2015 February 23–26; Seattle, WA.
  56. [Internet]. Bethesda (MD): National Library of Medicine (U.S.). 2000. Identifier NCT02362503, Attachment inhibitor comparison in heavily treatment experienced patients; 2015 February 9.
  57. Feinberg J, Thompson M, Cade J, et al. Final week 48 analysis of cenicriviroc (CVC) compared to efavirenz (EFV), in combination with emtricitabine/tenofovir (FTC/TDF), in treatment-naïve HIV-1-infected adults with CCR5-tropic virus (Abstract PS4/1). 2013 EACS; 2013 October 16–19; Brussels, Belgium.
  58. Visseaux BF, Charpentier C, Bertine M, et al. Cenicriviroc, a novel CCR5 (R5) and CCR2 antagonist, shows in vitro activity against R5 tropic HIV-2 clinical isolates (Abstract 75). International Workshop on Antiviral Drug Resistance; 2014 June 3–7; Berlin, Germany. Antiviral Therapy 2014;19(Suppl 1):A115.
  59. [Internet]. Bethesda (MD): National Library of Medicine (U.S.). 2000. Identifier NCT02128828, Effect of cenicriviroc on HIV neurocognitive impairment; 2013 September 4.
  60. [Internet]. Bethesda (MD): National Library of Medicine (U.S.). 2000. Identifier NCT022217475, Efficacy and safety study of cenicriviroc for the treatment of NASH in adult subjects with liver fibrosis (CENTAUR); 2014 August 13.
  61. Eron JJ, Rockstroh JK, Reynes J, et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomized, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis. 2001 Dec;11(12):907–15.
  62. Rizk ML, Krishna R, Schulz, ten Bruggencate-Broeders J, Larson P, Wenning L. A multiple dose study of raltegravir formulations (Abstract 523). 21st CROI; 2014 March 3–6; Boston, MA.
  63. [Internet]. Bethesda (MD): National Library of Medicine (U.S.). 2000. Identifier NCT02131233, Evaluation of the safety and efficacy of reformulated raltegravir (MK-0518) 1200 mg once daily in combination with Truvada in human immunodeficiency virus (HIV)-1 infected, treatment-naïve participants (MK-0518-292) (onceMRK); 2014 May 2.
  64. Zeyu L, Cantone J, Protack T, et al. Maturation inhibitor mechanistic studies – differential inhibition of Gag polymorphs (Abstract 539). 22nd CROI; 2015 February 23–26; Seattle, WA.
  65. Hwang C, Sevinsky H, Ravindran P, et al. Antiviral activity/safety of a second-generation HIV-1 maturation inhibitor (Abstract 114LB). 22nd CROI; 2015 February 23-26; Seattle, WA.
  66. [Internet]. Bethesda (MD): National Library of Medicine (U.S.). 2000. Identifier NCT02273947, Food effect study with
    BMS-955176; 2014 October 10.
  67. [Internet]. Bethesda (MD): National Library of Medicine (U.S.). 2000. Identifier NCT0415595, Dose-finding study of
    BMS-955176 to treat HIV-1 infected treatment-naïve adults; 2015 March 11.
  68. [Internet]. Bethesda (MD): National Library of Medicine (U.S.). 2000. Identifier NCT02386098, Strategy-confirming study of BMS-955176 to treat HIV-1 infected treatment-experienced adults; 2015 March 6.
  69. [Internet]. Bethesda (MD): National Library of Medicine (U.S.). 2000. Identifier NCT02275065, Safety, pharmacokinetics, and antiviral activity of GS-9883 in HIV-1 infected subjects; 2014 October 23.
  70. [Internet]. Bethesda (MD): National Library of Medicine (U.S.). 2000. Identifier NCT02397695, Safety and efficacy of GS-9883 + emtricitabine/tenofovir alafenamide versus dolutegravir + emtricitabine/tenofovir alafenamide in HIV-1 infected, antiretroviral treatment-naïve adults; 2015 March 20.
  71. Yoshinaga T, Kobayashi M, Seki T, et al. Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection. Antimicrob Agents Chemother. 2014 Nov 3.
  72. Spreen W, Williams P, Margolis D, et al. Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults. J Acq Immune Def Syndr. 2014;67(5):487–492.
  73. Y. Lou, E. Gould, S. Chen, et al. Meta-analysis of safety data from 8 clinical studies with GSK1265744, an HIV integrase inhibitor, dosed
    orally or as injection of long-acting parenteral nanosuspension (Abstract H-672). 53rd ICAAC; 2013 September 10–13; Denver, CO.
  74. Margolis D, Griffith S, St. Clair M, et al. Cabotegravir and rilpivirine as 2-drug oral maintenance therapy: LATTE W96 results (Abstract 554LB). 22nd CROI; 2015 February 23–26; Seattle, WA.
  75. [Internet]. Bethesda (MD): National Library of Medicine (U.S.). 2000. Identifier NCT02345707, Relatively bioavailability study of phase III tablet formulation of cabotegravir; 2015 January 18.
  76. [Internet]. Bethesda (MD): National Library of Medicine (U.S.). 2000. Identifier NCT02120352, A phase IIb study to evaluate a long-acting intramuscular regimen for maintenance of virologic suppression (following induction with an oral regimen of GSK1265744 and abacavir/lamivudine) in human immunodeficiency virus type 1 (HIV-1) infected, antiretroviral therapy-naïve adult subjects; 2014 April 17.
  77. ViiV Healthcare (Press Release). ViiV Healthcare announces new collaboration with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1. 2014 June 12.
  78. [Internet]. Bethesda (MD): National Library of Medicine (U.S.). 2000. Identifier NCT02373930, Relative oral bioavailability study of different fixed dose combinations of dolutegravir and rilpivirine in healthy subject; 2015 February 23.
  79. [Internet]. Bethesda (MD): National Library of Medicine (U.S.). 2000. Identifier NCT02302547, Trial to evaluate the interest of a reductive anti retroviral strategy using dual therapy in spite of triple therapy (TRULIGHT); 2014 October 14.
  80. [Internet]. Bethesda (MD): National Library of Medicine (U.S.). 2000. Identifier NCT02422797, Regimen switch to dolutegravir + rilpivirine from current antiretroviral regimen in human immunodeficiency virus type 1 infected and virologically suppressed adults (SWORD-2); 2015 April 9.
  81. [Internet]. Bethesda (MD): National Library of Medicine (U.S.). 2000. Identifier NCT02069834, Dolutegravir + rilpivirine switch study (DORISS); 2014 February 18.
  82. Gupta SK, Lombaard J, Echevarría J, et al. HIV NRTI BMS-986001 in antiretroviral-naïve subjects: Week 24/48 analyses (Abstract H-642). 54th ICAAC; 2014 September 5–9; Washington, D.C.
  83. McComsey GA, Gupta SK, Orrell C, et al. HIV NRTI BMS-986001 in antiretroviral-naive subjects: evaluation of bone and metabolic safety data through week 48 (Abstract H-1644). 54th ICAAC; 2014 September 5–9; Washington, D.C.
  84. Smith RA, Raugi DN, Parker K, et al. BMS-986001: A promising candidate for HIV-2 treatment (Abstract 61). International HIV Drug Resistance Workshop; 2015 February 21–22; Seattle, WA.
  85. Caskey M, Klein F, Lorenzi JC, et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015 Apr 8. [Epub ahead of print]
  86. [Internet]. Bethesda (MD): National Library of Medicine (U.S.). 2000. Identifier NCT01056393, Investigator-sponsored protocol – continued use of ibalizumab; 2014 April 7.
  87. [Internet]. Bethesda (MD): National Library of Medicine (U.S.). 2000. Identifier NCT02028819, Compassionate use of ibalizumab for the treatment of HIV infection; 2014 January 3.
  88. Ernst J, Keefer M, Lalezari J, et al. Subcutaneous ibalizumab in at-risk healthy subjects (Abstract H-995). ICAAC 2014; 2014 September 5–9; Washington, D.C.
  89. Jacbson JM, Saag MS, Thompson MA, et al. Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. J Infect Dis. 2008 Nov 1;198(9):1245–52.
  90. Jacobson JM, Lalezari JP, Thompson MA, et al. Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults. Antimicrob Agents Chemother. 2010 Oct;54(10)4137–42.
  91. Jacobson JM, Thompson MA, Lalezari JP, et al. Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. J Infect Dis. 2010 May 15;201(101):1481–7.
  92. [Internet]. Bethesda (MD): National Library of Medicine (U.S.). 2000. Identifier NCT02175680, Treatment substitution with PRO 140 monotherapy in adult subjects with HIV-1 infection; 2014 June 24.
  93. [Internet]. Bethesda (MD): National Library of Medicine (U.S.). 2000. Identifier NCT01272258, A trial of observed long-acting, anti-HIV treatment with a monoclonal CCR5 antibody (PRO 140) as an adjunct to a new, optimized, oral antiretroviral regimen in HIV-infected injection drug users with viral rebound and documented poor adherence; 2011 January 5.
Back To Top